B-cell lymphoma natural history, complications and prognosis

Jump to navigation Jump to search

B-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell lymphoma natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell lymphoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell lymphoma natural history, complications and prognosis

CDC on B-cell lymphoma natural history, complications and prognosis

B-cell lymphoma natural history, complications and prognosis in the news

Blogs on B-cell lymphoma natural history, complications and prognosis

Directions to Hospitals Treating B-cell lymphoma

Risk calculators and risk factors for B-cell lymphoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]

Overview

B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas. 30% of patients with Hodgkin's lymphoma may progress to develop B symptoms. The natural history of Non-Hodgkin lymphomas significantly varies depending on the subtype and its prognosis. Complications of B cell lymphomas are usually due to side effects of chemotherapy and/or radiotherapy. Depending on the stage of the Hodgkin's lymphoma at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as excellent. The prognosis of non-Hodgkin's lymphoma (NHL) varies with the histopathology, the extent of involvement, and patient factors. Low-grade lymphomas have the most favorable prognosis.

Natural History, Complications, and Prognosis

B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas.

Natural History

  • 30% of patients with Hodgkin's lymphoma may progress to develop B symptoms (unintentional weight loss, fever, drenching night sweats)[1].
  • The natural history of Non-Hodgkin lymphomas significantly varies depending on the subtype and its prognosis. If left untreated, aggresive lymphomas present with B symptoms, and patients' condition significantly deteriorates within days or weeks. On the other hand, indolent lymphomas usually present with waxing and waning lymphadenopathy for years[2].

Complications

Prognosis

  • Depending on the stage of the Hodgkin's lymphoma at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as excellent.[1]
    • In patients with stage 1 or 2a Hodgkin's lymphoma, the 5-year overall survival is approximately 90%.
    • In patients with stage 4 Hodgkin's lymphoma, the 5-year overall survival is approximately 60%.
  • The prognosis of non-Hodgkin's lymphoma (NHL) varies with the histopathology, the extent of involvement, and patient factors. Low-grade lymphomas have the most favorable prognosis.[2][11]
    • International Prognostic Index (IPI) is the main prognostic tool for NHL to determine the risk, which consists of five factors, including age >60 years, an increased serum LDH level, more than one extranodal involvement, Eastern Cooperative oncology group (ECOG) performance status 2 or greater than 2, and clinical stage III or IV.
    • Patients with aggressive NK or T cell lymphomas generally have the worst prognosis. In addition, patients with immunodeficiency states have a poor response to treatment.

References

  1. 1.0 1.1 Kaseb H, Babiker HM. PMID 29763144. Missing or empty |title= (help)
  2. 2.0 2.1 2.2 2.3 Sapkota S, Shaikh H. PMID 32644754 Check |pmid= value (help). Missing or empty |title= (help)
  3. 3.0 3.1 Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015
  4. 4.0 4.1 "Radiation Therapy for Hodgkin Lymphoma | Radiation for Hodgkin Disease".
  5. Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE (December 2015). "Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma". N Engl J Med. 373 (26): 2499–511. doi:10.1056/NEJMoa1505949. PMID 26699166.
  6. Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J (February 2006). "[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]". Pathologe (in German). 27 (1): 47–52. doi:10.1007/s00292-005-0811-0. PMID 16369761.
  7. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM (February 2000). "Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood". J Clin Oncol. 18 (3): 487–97. doi:10.1200/JCO.2000.18.3.487. PMID 10653864.
  8. 8.0 8.1 Ng AK, LaCasce A, Travis LB (May 2011). "Long-term complications of lymphoma and its treatment". J Clin Oncol. 29 (14): 1885–92. doi:10.1200/JCO.2010.32.8427. PMID 21483015.
  9. Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK (January 2011). "Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation". Blood. 117 (2): 412–8. doi:10.1182/blood-2010-06-291328. PMID 20858859.
  10. Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U (January 2015). "The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma". Leuk Lymphoma. 56 (1): 12–25. doi:10.3109/10428194.2014.894187. PMID 24559287.
  11. "Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma".


Template:WikiDoc Sources